Annals of Surgical Oncology

, Volume 17, Issue 8, pp 2081–2089 | Cite as

Predictive Factors for Hypertrophy of the Future Remnant Liver After Selective Portal Vein Embolization

  • Thierry de Baere
  • Christophe Teriitehau
  • Frederic Deschamps
  • Laurence Catherine
  • Pramod Rao
  • Antoine Hakime
  • Anne Auperin
  • Diane Goere
  • Dominique Elias
  • Lukas Hechelhammer
Hepatobiliary Tumors



To analyze predictive factors of hypertrophy of the nonembolized future remnant liver (FRL) after transhepatic preoperative portal vein embolization (PVE) of the liver to be resected.

Materials and Methods

Age, gender, indocyanin green clearance test, chemotherapy before PVE, type of chemotherapy, operators, extent of PVE, radiofrequency ablation (RFA) associated with PVE, time delay between PVE and surgery, and platelet count were retrospectively evaluated as predictive factors for hypertrophy of FRL in 107 patients with malignant disease in noncirrhotic liver. PVE targeted the right liver lobe [n = 70] or the right liver lobe and segment IV [n = 37] when FRL/total liver volume ratio was below 25% in healthy liver or 40% in altered liver.


After PVE, FRL volume significantly increased by 69%, from 344 ± 156 cm3 to 543 ± 192 cm3 (P < .0001). The degree of hypertrophy was negatively correlated with FRL volume (correlation coefficient = −0.55, P < .0001) and FRL/TFL ratio (correlation coefficient = −0.52, P < .0001) before PVE. Patients, who have undergone chemotherapy with platin agents prior to PVE, demonstrated lower hypertrophy (P = .048).


Hypertrophy after PVE is inversely correlated to initial FRL volume. Hypertrophy of the liver might be influenced by the systemic chemotherapeutic received before PVE.


Portal Vein Embolization Future Remnant Liver Portal Branch Portal Vein Branch Future Remnant Liver Volume 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors thank Joey Marie Robinson for editing the manuscript.


  1. 1.
    Shirabe K, Shimada M, Gion T, Hasegawa H, Takenaka K, Utsunomiya T, et al. Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg. 1999;188:304–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN. Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg. 2002;137:675–80; discussion 680–1.CrossRefPubMedGoogle Scholar
  3. 3.
    Shoup M, Gonen M, D’Angelica M, Jarnagin WR, DeMatteo RP, Schwartz LH, et al. Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg. 2003;7:325–30.CrossRefPubMedGoogle Scholar
  4. 4.
    Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–57; discussion 657–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Azoulay D, Castaing D, Smail A, Adam R, Cailliez V, Laurent A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg. 2000;231:480–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Yigitler C, Farges O, Kianmanesh R, Regimbeau JM, Abdalla EK, Belghiti J. The small remnant liver after major liver resection: how common and how relevant? Liver Transpl. 2003;9:S18–25.CrossRefPubMedGoogle Scholar
  7. 7.
    Kinoshita H, Sakai K, Hirohashi K, Igawa S, Yamasaki O, Kubo S. Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg. 1986;10:803–8.CrossRefPubMedGoogle Scholar
  8. 8.
    de Baere T, Roche A, Vavasseur D, Therasse E. Portal vein embolisation: utility for inducing left hepatic lobe hypertrophy before surgery. Radiology. 1993;188:73–7.PubMedGoogle Scholar
  9. 9.
    Nagino M, Kamiya J, Nishio H, Ebata T, Arai T, Nimura Y. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg. 2006;243:364–72.CrossRefPubMedGoogle Scholar
  10. 10.
    Madoff DC, Abdalla EK, Vauthey JN. Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care. J Vasc Interv Radiol. 2005;16:779–90.PubMedGoogle Scholar
  11. 11.
    Yamanaka N, Okamoto E, Kawamura E, Kato T, Oriyama T, Fujimoto J, et al. Dynamics of normal and injured human liver regeneration after hepatectomy as assessed on the basis of computed tomography and liver function. Hepatology. 1993;18:79–85.CrossRefPubMedGoogle Scholar
  12. 12.
    Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg. 2003;237:686–91; discussion 691–3.CrossRefPubMedGoogle Scholar
  13. 13.
    de Baere T, Roche A, Elias D, Lasser P, Lagrange C, Bousson V. Preoperative portal vein embolization for extension of hepatectomy indications. Hepatology. 1996;24:1386–91.CrossRefPubMedGoogle Scholar
  14. 14.
    Elias D, Santoro R, Ouellet JF, Osmak L, de Baere T, Roche A. Simultaneous percutaneous right portal vein embolization and left liver tumor radiofrequency ablation prior to a major right hepatic resection for bilateral colorectal metastases. Hepatogastroenterology. 2004;51:1788–91.PubMedGoogle Scholar
  15. 15.
    Imamura H, Shimada R, Kubota M, Matsuyama Y, Nakayama A, et al. Preoperative portal vein embolization: an audit of 84 patients. Hepatology. 1999;29:1099–105.CrossRefPubMedGoogle Scholar
  16. 16.
    Kaido T, Arii S, Shimada Y, Mori A, Imamura M. Portal embolization in various types of liver: novel variables to predict hypertrophy. Hepatogastroenterology. 2003;50:140–5.PubMedGoogle Scholar
  17. 17.
    Fujii Y, Shimada H, Endo I, Morioka D, Nagano Y, Miura Y, et al. Risk factors of posthepatectomy liver failure after portal vein embolization. J Hepatobiliary Pancreat Surg. 2003;10:226–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Goere D, Farges O, Leporrier J, Sauvanet A, Vilgrain V, Belghiti J. Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg. 2006;10:365–70.CrossRefPubMedGoogle Scholar
  19. 19.
    Kobayashi S, Nagino M, Yokoyama Y, Nimura Y, Sokabe M. Evaluation of hepatic interleukin-6 secretion following portal vein ligation using a minimal surgical stress model. J Surg Res. 2006;135:27–33.CrossRefPubMedGoogle Scholar
  20. 20.
    Nanashima A, Sumida Y, Shibasaki S, Takeshita H, Hidaka S, Sawai T, et al. Parameters associated with changes in liver volume in patients undergoing portal vein embolization. J Surg Res. 2006;133:95–101.CrossRefPubMedGoogle Scholar
  21. 21.
    Ogata S, Belghiti J, Farges O, Varma D, Sibert A, Vilgrain V. Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg. 2006;93:1091–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Denys A, Lacombe C, Schneider F, Madoff DC, Doenz F, Qanadli SD, et al. Portal vein embolization with N-butyl cyanoacrylate before partial hepatectomy in patients with hepatocellular carcinoma and underlying cirrhosis or advanced fibrosis. J Vasc Interv Radiol. 2005;16:1667–74.PubMedGoogle Scholar
  23. 23.
    Covey AM, Tuorto S, Brody LA, Sofocleous CT, Schubert J, von Tengg-Kobligk H, et al. Safety and efficacy of preoperative portal vein embolization with polyvinyl alcohol in 58 patients with liver metastases. AJR Am J Roentgenol. 2005;185:1620–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Nagino M, Ando M, Kamiya J, Uesaka K, Sano T, Nimura Y. Liver regeneration after major hepatectomy for biliary cancer. Br J Surg. 2001;88:1084–91.CrossRefPubMedGoogle Scholar
  25. 25.
    Tani M, Tomiya T, Yamada S, Hayashi S, Yahata K, Tamura Y. Regulating factors of liver regeneration after hepatectomy. Cancer Chemother Pharmacol. 1994;33:S29–S32.CrossRefPubMedGoogle Scholar
  26. 26.
    Bucher NL, Swaffield MN. The rate of incorporation of labeled thymidine into the deoxyribonucleic acid of regenerating rat liver in relation to the amount of liver excised. Cancer Res. 1964;24:1611–25.PubMedGoogle Scholar
  27. 27.
    Yuceturk H, Yagmurdur MC, Gur G, Demirbilek M, Bilezikci B, Turan M, et al. Role of heparin on TNF-alpha and IL-6 levels in liver regeneration after partial hepatic resection. Eur Surg Res. 2007;39:216–21.CrossRefPubMedGoogle Scholar
  28. 28.
    Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–72.CrossRefPubMedGoogle Scholar
  30. 30.
    Beal IK, Anthony S, Papadopoulou A, Hutchins R, Fusai G, Begent R, et al. Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. Br J Radiol. 2006;79:473–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Covey AM, Brown KT, Jarnagin WR, Brody LA, Schwartz L, Tuorto S, et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg. 2008;247:451–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol. 2008;15:2765–72.CrossRefPubMedGoogle Scholar
  34. 34.
    Nagino M, Kamiya J, Kanai M, Uesaka K, Sano T, Yamamoto H, et al. Right trisegment portal vein embolization for biliary tract carcinoma: technique and clinical utility. Surgery. 2000;127:155–60.CrossRefPubMedGoogle Scholar
  35. 35.
    Kishi Y, Madoff DC, Abdalla EK, Palavecino M, Ribero D, Chun YS, et al. Is embolization of segment 4 portal veins before extended right hepatectomy justified? Surgery. 2008;144:–74451.Google Scholar
  36. 36.
    de Baere T, Denys A, Paradis V. Comparison of four embolic materials for portal vein embolization: experimental study in pigs. Eur Radiol. 2009;19:1435–41.CrossRefPubMedGoogle Scholar
  37. 37.
    Breen DJ, Rutherford EE, Stedman B, Lee-Elliott C, Hacking CN. Intrahepatic arterioportal shunting and anomalous venous drainage: understanding the CT features in the liver. Eur Radiol. 2004;14:2249–60.CrossRefPubMedGoogle Scholar
  38. 38.
    Arai K, Matsui O, Takashima T, Ida M, Nishida Y. Focal spared areas in fatty liver caused by regional decreased portal flow. AJR Am J Roentgenol. 1988;151:300–2.PubMedGoogle Scholar
  39. 39.
    Takayasu K, Aoki K, Ichikawa T, Ohmura T, Sekiguchi R, Terauchi T, et al. Aberrant right gastric vein directly communicating with left portal vein system. Incidence and implications. Acta Radiol. 1990;31:575–7.PubMedGoogle Scholar
  40. 40.
    Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, et al. Platelet-derived serotonin mediates liver regeneration. Science. 2006;312:104–7.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2010

Authors and Affiliations

  • Thierry de Baere
    • 1
  • Christophe Teriitehau
    • 1
  • Frederic Deschamps
    • 1
  • Laurence Catherine
    • 1
  • Pramod Rao
    • 1
  • Antoine Hakime
    • 1
  • Anne Auperin
    • 2
  • Diane Goere
    • 3
  • Dominique Elias
    • 3
  • Lukas Hechelhammer
    • 1
  1. 1.Department of Interventional RadiologyInstitut Gustave RoussyVillejuifFrance
  2. 2.Department of BiostatisticsInstitut Gustave RoussyVillejuifFrance
  3. 3.Department of Surgical OncologyInstitut Gustave RoussyVillejuifFrance

Personalised recommendations